Literature DB >> 19390550

Hematology: Bortezomib in newly diagnosed multiple myeloma.

James R Berenson1.   

Abstract

Preclinical studies have shown that new agents such as bortezomib not only demonstrate anti-multiple-myeloma activity as single agents but also enhance the efficacy of both chemotherapy and steroids. A randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19390550     DOI： 10.1038/nrclinonc.2009.47

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

2.  Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Authors:  James R Berenson; Hank H Yang; Karen Sadler; Supol G Jarutirasarn; Robert A Vescio; Russell Mapes; Matthew Purner; Shi-pyng Lee; Joanna Wilson; Blake Morrison; Julian Adams; David Schenkein; Regina Swift
Journal:  J Clin Oncol       Date:  2006-01-17       Impact factor: 44.544

3.  Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.

Authors:  James R Berenson; Ralph Boccia; David Siegel; Marek Bozdech; Alberto Bessudo; Edward Stadtmauer; J Talisman Pomeroy; Ronald Steis; Marshall Flam; Jose Lutzky; Syed Jilani; Joseph Volk; Siu-Fun Wong; Robert Moss; Ravi Patel; Delina Ferretti; Kit Russell; Robert Louie; Howard S Yeh; Regina A Swift
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

4.  Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

Authors:  W Pönisch; P S Mitrou; K Merkle; M Herold; M Assmann; G Wilhelm; K Dachselt; P Richter; V Schirmer; A Schulze; R Subert; B Harksel; N Grobe; E Stelzer; M Schulze; A Bittrich; M Freund; R Pasold; Th Friedrich; W Helbig; D Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-10       Impact factor: 4.553

5.  A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.

Authors:  James R Berenson; Ori Yellin; Ravi Patel; Herb Duvivier; Youram Nassir; Russell Mapes; Christina DiLauro Abaya; Regina A Swift
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

6.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Tommaso Caravita; Emanuela Merla; Vincenzo Capparella; Vincenzo Callea; Clotilde Cangialosi; Mariella Grasso; Fausto Rossini; Monica Galli; Lucio Catalano; Elena Zamagni; Maria Teresa Petrucci; Valerio De Stefano; Manuela Ceccarelli; Maria Teresa Ambrosini; Ilaria Avonto; Patrizia Falco; Giovannino Ciccone; Anna Marina Liberati; Pellegrino Musto; Mario Boccadoro
Journal:  Lancet       Date:  2006-03-11       Impact factor: 79.321

7.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

8.  The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Authors:  Mark H Ma; Hank H Yang; Kimberly Parker; Steven Manyak; Jeffrey M Friedman; Cibby Altamirano; Zhi-qun Wu; Mitesh J Borad; Malka Frantzen; Evanthia Roussos; Jason Neeser; Amy Mikail; Julian Adams; Nelida Sjak-Shie; Robert A Vescio; James R Berenson
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

9.  Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

Authors:  Donna E Reece; Giovanni Piza Rodriguez; Christine Chen; Suzanne Trudel; Vishal Kukreti; Joseph Mikhael; Mariela Pantoja; Wei Xu; A Keith Stewart
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

10.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.